Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Qiagen NV    QGEN   NL0000240000

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

QIAGEN NV : Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Second Quarter 2010 Financial Results Call Set for August 10

share with twitter share with LinkedIn share with facebook
share via e-mail
08/03/2010 | 02:05pm CEST

VENLO, The Netherlands, Aug. 3 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: QGEN) today announced the Webcast of its second quarter 2010 financial results call. The Webcast will take place at 9:30 a.m. EDT on Tuesday, August 10, and will include remarks by Peer M. Schatz, President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer.

                    Webcast of QIAGEN's second quarter 2010 financial
    What:            results call

    When:           9:30 a.m. EDT on August 10

                    The Webcast is accessible at www.qiagen.com/goto/
    Where:           ConferenceCall

    How:            Log on to the Web at the address above

                    The corresponding presentation slides will be
                    available for download in the investor relations
                    section of QIAGEN's Web site at www.qiagen.com/

                    Andreas Marathovouniotis, Russo Partners, (212)
    Contact:        845-4235

QIAGEN N.V., a Netherlands holding company, is the leading provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include what is considered to be the broadest panel of molecular diagnostic tests available worldwide. This panel includes the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer.

QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at www.qiagen.com.

(Minimum Requirements to listen to broadcast: The RealPlayer software, downloadable free from http://www.real.com/products/player/index.html, or The Windows Media Player, downloadable free from www.microsoft.com and at least a 14.4Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to [email protected])


share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on QIAGEN NV
09/06 QIAGEN : N.V. launches non-US offering of cash settled convertible notes combine..
09/06 QIAGEN : Ad-hoc announcement pursuant to Art. 17 MAR
08/21 QIAGEN : and Clinical Genomics Partner on Liquid Biopsies to Monitor Patients fo..
07/27 QIAGEN : Reports Results for Second Quarter and First Half of 2017
07/27 QIAGEN : reports results for second quarter and first half of 2017
07/24QIAGEN NV : half-yearly earnings release
07/04 QIAGEN : French health-system approves reimbursement of QIAGEN's QuantiFERON lat..
07/04 QIAGEN : receives U.S. FDA approval for cytomegalovirus (CMV) testing on automat..
07/04 QIAGEN : DiaSorin and QIAGEN sign collaboration to expand liaison test menu thro..
07/04 QIAGEN : QuantiFERON®-TB Gold Plus gains U.S. FDA approval
More news
News from SeekingAlpha
01/17 Even A $100M Series A Can't Save The Medtech Venture Climate
01/17 Qiagen (QGEN) Presents At German Corporate Conference 2017
01/11 Qiagen NV (QGEN) presents at 35th Annual J.P. Morgan Healthcare Conference
2016 Qiagen N.V. 2016 Q3 - Results - Earnings Call Slides